

Instructions for Authors 2019

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Conflicts of Interest*; (h) *Authors' contributions*; (i) *Acknowledgements*; (j) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

Tables. All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

References. Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the form below and must be numbered consecutively. In the text, references should be cited by number in parenthesis. Examples: 1 Kenyon J, Liu W and Dagleish A: Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. *Anticancer Res* 38(10): 5831-5835, 2018. PMID: 30275207. DOI: 10.21873/anticancer.12924. (PMIDs and DOIs only if applicable). 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones*. O' Malley BW, Chamnes GC (eds.). New York, Plenum Publ Corp., pp 113-136, 1973. 3 Global Health Estimates 2015: Disease Burden by Cause, Age, Sex, by Country and by Region, 2000-2015. Geneva, World Health Organisation, 2016. Available at http://www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html. Last accessed on 3rd April 2018. (The web address should link directly to the cited information and not to a generic webpage).

Nomenclature and Abbreviations. Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human fetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iiar-submissions.com/login.html> In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: journals@iiar-anticancer.org

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004 (upon request to the Subscriptions Office). Galley proofs should be returned corrected to the Editorial Office by email (iiar@iiar-anticancer.org) within two days.

Specific information and additional instructions for Authors

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.
5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author’s writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.

6. Authors should pay attention to the following points when writing an article for AR:
 - The Instructions to Authors must be followed in every detail.
 - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
 - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
 - Results given in figures should not be repeated in tables.
 - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
 - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
 - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
 - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
 - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
 - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
 - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
 7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
 8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
 9. Articles submitted to AR may be rejected without review if:
 - they do not fall within the journal's policy.
 - they do not follow the instructions for authors.
 - language is unclear.
 - results are not sufficient to support a final conclusion.
 - results are not objectively based on valid experiments.
 - they repeat results already published by the same or other authors before the submission to AR.
 - plagiarism is detected by plagiarism screening services.(Rejection rate (2016): 66%).
 10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
 11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iiar-anticancer.org
 12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
 13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service.
- (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

Copyright© 2019 - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

Initial Experience With Radium-223 Chloride Treatment at the Kanazawa University Hospital. K. NAKASHIMA, T. MAKINO, S. KADOMOTO, H. IWAMOTO, H. YAEGASHI, M. IIJIMA, S. KAWAGUCHI, T. NOHARA, K. SHIGEHARA, K. IZUMI, Y. KADONO, S. MATSUO, A. MIZOKAMI (Kanazawa; Ishikawa, Japan)	2607
Efficacy and Safety of Enoxaparin for Prophylaxis of Postoperative Venous Thromboembolism After Esophagectomy: A Single-center Prospective Randomized Controlled Phase II Study. Y. TANAKA, A. YAMADA, S. HIRATA, H. TANAKA, T. SAKURATANI, N. MATSUHASHI, K. YAMAGUCHI, T. SHIMOKAWA, K. YOSHIDA (Gifu; Wakayama, Japan).....	2615
A Case Report of Adult Pineoblastoma Occurring in a Pregnant Woman. F. CUCCIA, G. MORTELLARO, D. CESPUGLIO, V. VALENTI, G. DE GREGORIO, E. QUARTUCCIO, L. BLASI, N. FRANCAVIGLIA, C. GALLO, A. LO CASTO, G. FERRERA (Palermo, Italy)	2627
Long-term Quality of Life of Melanoma Survivors Is Comparable to that of the General Population. P.J. HEINO, P.H. MYLLÄRI, T.A. JAHKOLA, H. SINTONEN, M.-L. LUOMA, P. RÄSÄNEN, R.P. ROINE (Helsinki; Kuopio, Finland).....	2633
Clinical Usefulness of Perioperative C-reactive Protein/Albumin Ratio in Patients With Intrahepatic Cholangiocarcinoma: A Retrospective Single Institutional Study. Y. NAKAO, Y.-I. YAMASHITA, K. ARIMA, T. MIYATA, R. ITOYAMA, T. YUSA, N. UMEZAKI, T. YAMAO, S. NAKAGAWA, H. OKABE, K. IMAI, A. CHIKAMOTO, H. BABA (Kumamoto, Japan)	2641
The Role of Previous Therapies and Sites of Metastasis as Influencing Factors on Discordance of ER, PR and HER2 Status Between Primary and Metastasized Breast Cancer. C. VOGEL, W. MALTER, B. MORGENSTERN, S. LUDWIG, J.J. VEHRERESCHILD, S. HAMACHER, P. MALLMANN, V. KIRN, F. THANGARAJAH (Cologne, Germany)	2647
Comparison of Minimally Invasive Surgery and Abdominal Surgery Among Patients With Cervical Cancer. D. RATIU, C. LUNCESCU, B. MORGENSTERN, C. EICHLER, B. GRÜTTNER, S. LUDWIG, P. MALLMANN, F. THANGARAJAH (Cologne, Germany)	2661
Prognosis of Early-stage Part-solid and Pure-solid Lung Adenocarcinomas. F. KINOSHITA, G. TOYOKAWA, T. MATSUBARA, Y. KOZUMA, N. HARATAKE, S. TAKAMORI, T. AKAMINE, F. HIRAI, T. TAKENAKA, T. TAGAWA, Y. MAEHARA (Fukuoka; Hiroshima, Japan).....	2665
Influence of Postoperative Pneumonia on Esophageal Cancer Survival and Recurrence. A. TAMAGAWA, T. AOYAMA, H. TAMAGAWA, M. JU, K. KOMORI, Y. MAEZAWA, K. KANO, K. KAZAMA, M. MURAKAWA, Y. ATSUMI, S. SAWAZAKI, K. HARA, M. NUMATA, T. SATO, N. YUKAWA, M. MASUDA, Y. RINO (Kanazawa, Japan)	2671
Book Reviews	2679
Announcements.....	2681

Clinical Outcome of Patients With Malignant Tumors Associated With Mature Cystic Teratomas of the Ovary: A Retrospective Multicenter Italian Study. A. GADDUCCI, D. GIULIANI, S. COSIO, A. LISSONI, A.M. FERRERO, F. LANDONI (<i>Pisa; Milan; Turin, Italy</i>)	2513
The Utility of Optical Instrument “ORALOOK®” in the Early Detection of High-risk Oral Mucosal Lesions. T. MORIKAWA, A. KOSUGI, T. SHIBAHARA (<i>Chiba, Japan</i>)	2519
Survival Rates According to Tumour Location in Patients With Surgically-treated Oral and Oropharyngeal Squamous Cell Carcinoma. P. JEHN, J. DITTMANN, R. ZIMMERER, R. STIER, M. JEHN, N.-C. GELLRICH, F. TAVASSOL, S. SPALTHOFF (<i>Hannover, Germany</i>)	2527
Role of Amino Acid Transporter Expression as a Prognostic Marker in Patients With Surgically Resected Colorectal Cancer. H. OGAWA, K. KAIRA, Y. MOTEGI, T. YOKOBORI, T. TAKADA, R. KATOH, K. OSONE, R. TAKAHASHI, C. KATAYAMA, T. OYAMA, Y. KANAI, T. YAO, T. ASAO, H. KUWANO, K. SHIRABE (<i>Gunma; Saitama; Osaka; Tokyo, Japan</i>)	2535
Comparison of Clinical Outcomes of Gastrojejunal Bypass and Gastrectomy in Patients With Metastatic Gastric Cancer. D. MATSUBARA, H. KONISHI, T. KUBOTA, T. KOSUGA, K. SHODA, A. SHIOZAKI, H. FUJIWARA, K. OKAMOTO, E. OTSUJI (<i>Kyoto, Japan</i>)	2545
Quantification of Bone Metastasis of Castration-resistant Prostate Cancer After Enzalutamide and Abiraterone Acetate Using Bone Scan Index on Bone Scintigraphy. S. KADOMOTO, H. YAEGASHI, K. NAKASHIMA, M. IJIMA, S. KAWAGUCHI, T. NOHARA, K. SHIGEHARA, K. IZUMI, Y. KADONO, K. NAKAJIMA, A. MIZOKAMI (<i>Kanazawa, Japan</i>)	2553
Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-small Cell Lung Cancer. H. KAWACHI, D. FUJIMOTO, D. YAMASHITA, J. FUKUOKA, Y. KITAMURA, K. HOSOYA, Y. SATO, K. NAGATA, A. NAKAGAWA, R. TACHIKAWA, N. DATE, I. SAKANOUE, H. HAMAKAWA, Y. TAKAHASHI, K. TOMII (<i>Kobe; Nagasaki, Japan</i>)	2561
Diagnosis-specific WBRT-30-CRC Score for Estimating Survival of Patients Irradiated for Brain Metastases from Colorectal Cancer. D. RADES, H.C. HANSEN, S. JANSSEN, S.E. SCHILD (<i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i>)	2569
Diagnostic Power of Selected Cytokines, MMPs and TIMPs in Ovarian Cancer Patients – ROC Analysis. G.E. BĘDKOWSKA, B. PISKÓR, E. GACUTA, M. ZAJKOWSKA, J. OSADA, M. SZMITKOWSKI, M. DĄBROWSKA, S. ŁAWICKI (<i>Białystok, Poland</i>)	2575
Neutrophil-to-Lymphocyte Ratio as a Prognostic Indicator in Patients With Unresectable Gastric Cancer. Y. MURAKAMI, H. SAITO, S. SHIMIZU, Y. KONO, Y. SHISHIDO, K. MIYATANI, T. MATSUNAGA, Y. FUKUMOTO, Y. FUJIWARA (<i>Yonago, Japan</i>)	2583
Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in “Real-Life” Outside of Clinical Trials. S. SACHANAS, G.A. PANGALIS, A.-M. FINK, J. BAHLO, K. FISCHER, G. LEVIDOU, M.-C. KYRTSONIS, V. BARTZI, T.P. VASSILAKOPOULOS, C. KALPADAKIS, E. KOULIERIS, M. MOSCHOGIANNIS, X. YIAKOUMIS, P. TSIRKINIDIS, M.K. ANGELOPOULOU, B. EICHHORST, M. HALLEK (<i>Athens; Karditsa; Heraklion, Greece; Cologne; Erlangen, Germany</i>)	2591
A Retrospective Head-to-head Comparison Between TiLoop Bra/TiMesh® and Seragyn® in 320 Cases of Reconstructive Breast Surgery. C. EICHLER, C. SCHULZ, F. THANGARAJAH, W. MALTER, M. WARM, K. BRUNNERT (<i>Cologne; Osnabrueck, Germany</i>)	2599

Synthesis of ⁶⁸ Ga-Labeled Biopolymer-based Nanoparticle Imaging Agents for Positron-emission Tomography. Z. KÖRHEGYI, D. RÓZSA, I. HAJDU, M. BODNÁR, I. KERTÉSZ, K. KERÉKES, S. KUN, J. KOLLÁR, J. VARGA, I. GARAI, G. TRENCSENYI, J. BORBÉLY (<i>Debrecen, Hungary</i>)	2415
Perfluorooctanoic Acid Enhances Invasion of Follicular Thyroid Carcinoma Cells Through NF-κB and Matrix Metalloproteinase-2 Activation. P. SAEJIA, K. LIRDPRAPAMONGKOL, J. SVASTI, N.M. PARICHARTTANAKUL (<i>Bangkok, Thailand</i>)	2429
Investigation of Caspase 9 Gene Polymorphism in Patients With Non-small Cell Lung Cancer. S. ERCAN, S. ARINC, S.G. YILMAZ, C. ALTUNOK, F. YAMAN, T. ISBIR (<i>Istanbul, Turkey</i>)	2437
Platelet Depletion/Transfusion as a Lethal Factor in a Colitis-associated Cancer Mouse Model. A. ANGELOU, E. ANTONIOU, A. PIKOULI, J. WANG, M. VENTIN, S. BUETTNER, M. FAATEH, G. THEODOROPOULOS, G.C. ZOGRAFOS, S. THEOCHARIS, A.E. PAPALOIS, E. PIKOULIS, G.A. MARGONIS (<i>Athens, Greece; Baltimore, MD, USA; Udine, Italy; Nicosia, Cyprus</i>)	2443
TP53 Tumor-suppressor Gene Plays a Key Role in IGF1 Signaling Pathway Related to the Aging of Human Melanocytes. H. KO, M.-M. KIM (<i>Busan, Republic of Korea</i>)	2447
Protective Effect of Melatonin on Cisplatin-induced Ototoxicity in Rats. J.G. DE ARAUJO, L.S.M. SERRA, L. LAUAND, S.A.S. KÜCKELHAUS, A.L.L. SAMPAIO (<i>Brasilia, Brazil</i>)	2453
<i>Clinical Studies</i>	
Prognostic Impact of Proximal Versus Distal Localization in Extremity Long Bone Osteosarcomas. K. BERNER, Ø.S. BRULAND (<i>Oslo, Norway</i>)	2459
Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression. D.J. BECKER, A.D. IYENGAR, S.R. PUNEKAR, J. NG, A. ZAMAN, S. LOEB, K.D. BECKER, D. MAKAROV (<i>New York; Brooklyn, NY, USA</i>)	2467
Annexin A2 and S100A10 as Candidate Prognostic Markers in Epithelial Ovarian Cancer. M.V. CHRISTENSEN, C. HØGDALL, S.G. JENSEN, N. LOKMAN, C. RICCIARDELLI, I.J. CHRISTENSEN, P. CHRISTIANSEN, J. BRASK, M.A. KARLSEN, T.K. NISSEN, K.M. JOCHUMSEN, E. HØGDALL (<i>Copenhagen; Odense, Denmark; Adelaide, Australia</i>)	2475
An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer. K. KAIRA, H. IMAI, R. SOUMA, R. SAKURAI, Y. MIURA, N. SUNAGA, N. KASAHARA, Y. TSUKAGOSHI, Y. KOGA, S. KITAHARA, M. KOTAKE, K. MINATO, I. NARUSE, Y. FUKUSHIMA, T. HISADA, T. ISHIZUKA (<i>Gunma; Saitama; Fukui, Japan</i>)	2483
Usefulness of 18-FDG PET/CT in Detecting Malignancy in Intraductal Papillary Mucinous Neoplasms of the Pancreas. Y.-I. YAMASHITA, H. OKABE, H. HAYASHI, K. IMAI, S. NAKAGAWA, Y. NAKAO, T. YUSA, R. ITOYAMA, T. YAMA, N. UMESAKI, K. ARIMA, T. MIYATA, A. CHIKAMOTO, H. BABA (<i>Kumamoto, Japan</i>)	2493
Radioablation of Hepatic Metastases from Renal Cell Carcinoma With Image-guided Interstitial Brachytherapy. J. OMARI, C. HEINZE, R. DAMM, P. HASS, A. JANITZKY, J.J. WENDLER, M. SEIDENSTICKER, J. RICKE, M.J. POWERSKI, M. PECH (<i>Magdeburg; Munich, Germany; Gdansk, Poland</i>)	2501
Percutaneous Irreversible Electroporation as First-line Treatment of Locally Advanced Pancreatic Cancer. C. MÅNSSON, R. BRAHMSTAEDT, P. NYGREN, A. NILSSON, J. URDZIK, B.-M. KARLSON (<i>Uppsala, Sweden</i>)	2509

Differential Prognostic Relevance of Promoter DNA Methylation of <i>CDO1</i> and <i>HOPX</i> in Primary Breast Cancer. Y. TANAKA, Y. KOSAKA, M. WARAYA, K. YOKOTA, H. HARADA, T. KAIDA, M. KIKUCHI, N. MINATANI, H. NISHIMIYA, H. KATOH, N. SENGOKU, M. WATANABE, K. YAMASHITA (<i>Sagamihara, Japan</i>)	2289
Death Receptor 6 (DR6) Is Overexpressed in Astrocytomas. S. STEGMANN, J.-M. WERNER, S. KUHL, G. RÖHN, B. KRISCHEK, P. STAVRINO, R. GOLDBRUNNER, M. TIMMER (<i>Cologne, Germany</i>)	2299
Hyperthermia Suppresses Post - <i>In Vitro</i> Proliferation and Tumor Growth in Murine Malignant Melanoma and Colon Carcinoma. T. MANTSO, S. VASILEIADIS, E. LAMPRI, S. BOTAITIS, S. PERENTE, C. SIMOPOULOS, K. CHLICHLIA, A. PAPPA, M.I. PANAYIOTIDIS (<i>Newcastle Upon Tyne; Edinburgh, UK; Alexandroupolis; Ioannina, Greece</i>)	2307
The Pathological Significance and Prognostic Roles of Thrombospondin -1, and -2, and 4N1K-peptide in Bladder Cancer. Y. NAKAMURA, Y. MIYATA, K. TAKEHARA, A. ASAI, K. MITSUNARI, K. ARAKI, T. MATSUO, K. OHBA, H. SAKAI (<i>Nagasaki, Japan</i>)	2317
MCM5 Expression Is Associated With the Grade of Malignancy and Ki-67 Antigen in LSCC. K. NOWINSKA, U. CIESIELSKA, A. PIOTROWSKA, K. JABLONSKA, A. PARTYNSKA, M. PAPROCKA, T. ZATONSKI, M. PODHORSKA-OKOLOW, P. DZIEGIEL (<i>Wroclaw, Poland</i>)	2325
Hypoxia Induced by Vascular Damage at High Doses Could Compromise the Outcome of Radiotherapy. E. KJELLSSON LINDBLOM, A. DASU, I. TOMA-DASU (<i>Stockholm; Linköping; Uppsala, Sweden</i>)	2337
Correlation of Expression of CHI3L1 and Nogo-A and their Role in Angiogenesis in Invasive Ductal Breast Carcinoma. A. RUSAK, K. JABLONSKA, A. PIOTROWSKA, J. GRZEGRZOLKA, A. WOJNAR, P. DZIEGIEL (<i>Wroclaw, Poland</i>)	2341
Activation of Hedgehog Signaling in Aggressive Hepatic Hemangioma in Newborns and Infants. D. WENDLING-KEIM, C. VOKUHL, C. WALZ, L. RIEDER, R. GRANTZOW, D. VON SCHWEINITZ, R. KAPPLER, M. BERGER (<i>Munich; Kiel, Germany</i>)	2351
Promoter Methylation Down-regulates Osteoprotegerin Expression in Ovarian Carcinoma. J.-Y. KIM, S.H. KIM, H.-S. KIM (<i>Seoul; Goyang, Republic of Korea</i>)	2361
Diallyl Trisulfide Enhances Benzo[a]pyrene-induced <i>CYP1A1</i> Expression and Metabolic Activation in Hepatic HepG2 Cells. S. UNO, M. SAKAI, Y. FUJINARI, T. HOSONO, T. SEKI, M. MAKISHIMA (<i>Tokyo; Kanagawa, Japan</i>).....	2369
Lapatinib Inhibits Amphiregulin-induced BeWo Choriocarcinoma Cell Proliferation by Reducing ERK1/2 and AKT Signaling Pathways. L.V. PIRES, Y. YI, J.-C. CHENG, L. SCHNEIDER PIZZOLATO, E. CORDERO, P.C.K. LEUNG, I.S. BRUM (<i>Porto Alegre, RS, Brazil; Vancouver, BC, Canada</i>)	2377
Nonsteroidal Anti-inflammatory Drugs Modulate Gene Expression of Inflammatory Mediators in Oral Squamous Cell Carcinoma. D.M. ANTUNES, M.F.S.D. RODRIGUES, D.M. GUIMARÃES, C.M.E. DUARTE, L. MIGUITA, L. CORRÊA, A.P.L. DE OLIVEIRA, K.P.S. FERNANDES, F.D. NUNES (<i>São Paulo; Grosso do Sul, Brazil</i>).....	2385
The Epigenetic Modifier 5-Aza-2-deoxycytidine Triggers the Expression of <i>CD146</i> Gene in Prostate Cancer Cells. P. DUDZIK, S.E. TROJAN, B. OSTROWSKA, G. ZEMANEK, J. DULIŃSKA-LITEWKA, P. LAIDLER, K.A. KOCEMBA-PILARCZYK (<i>Cracow, Poland</i>)	2395
Cold Atmospheric Plasma Induces HMGB1 Expression in Cancer Cells. Y. YOON, B. KU, K. LEE, Y.J. JUNG, S.J. BAEK (<i>Seoul; Seongnam, Republic of Korea</i>)	2405